Nov 24, 2020
The redirection of T cells against tumors holds significant promise for the treatment of cancer. Two main approaches for T-cell redirection involve their genetic modification with chimeric antigen receptors (CAR) or the use of bispecific antibodies that can bind to two different antigens simultaneously.
On this episode of CANCER BUZZ, learn about these
promising breakthroughs, the challenges facing their widespread
use, and what your cancer team needs to know about the future of
cancer treatment.
Guest: Firas El Chaer, MD, Assistant Professor of Medicine,
Department of Hematology and Oncology, University of Virginia,
Emily Couric Clinical Cancer Center
Related Content:
The views and opinions expressed herein are those of the
author(s)/faculty member(s) and do not reflect the official policy
or position of their employer(s) or the Association of Community
Cancer Centers.